Clinical trial

DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects

NCT01423812

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Twice-daily combination Darunavir and ritonavir Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Once-daily combination Darunavir and ritonavir Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-01-01

PhasePHASE4

Conditions

HIVunresolved

Interventions

Twice-daily combination Darunavir and ritonavirDRUG

Once-daily combination Darunavir and ritonavirDRUG

Sponsors & collaborators

Ruth M. Rothstein CORE Centerlead sponsor

Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USAcollaborator

Mapped research locations

ChicagoIllinois, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01423812 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.